Abstract:
A dosage form comprising a tablet core and one or more discontinuous coated regions in various configurations on the surface of the dosage form is disclosed. A method for making the dosage form is also disclosed.
Abstract:
The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
Abstract:
본 발명은 인슐린 비의존성 당뇨병 치료제인 메트포르민의 위 체류형 서방성 제제 및 이의 제조방법에 관한 것이다. 보다 구체적으로는 메트포르민 또는 이의 약학적으로 허용가능한 염과 팽윤성 고분자를 포함하는 과립 및 상기 과립 표면에 코팅된 수불용성 고분자 피막을 포함하는 서방출형 과립물을 형성하여 적은 분량의 고분자를 사용하면서도 효과적으로 약물의 방출을 제어할 수 있고, 수화겔을 형성하는 겔화 속도를 조절해주는 초붕해제를 상기 과립물과 함께 혼합하여 제형화함으로써 약물을 포함한 정제가 초기에 빠르게 팽윤될 수 있도록 하는 위 체류형 서방성 제제 및 이의 제조방법에 관한 것이다.
Abstract:
The invention provides ingestible particles comprising a water-swellable or water-soluble polymeric component, a lipid component, and optionally an amino acid, a vitamin and/or a micro-nutrient. The polymeric component may be embedded in the lipid component. The particle may further comprise an inert core and/or an outer layer which rapidly disintegrates after oral ingestion. The invention further provides methods for preparing the ingestible particles and uses thereof.
Abstract:
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a triazole antifungal agent or pharmaceutical acceptable salt thereof, in particular Voriconazole and an effective amount of a solubility enhancing agent. It also relates to a process for the preparation thereof.
Abstract:
Disclosed are methods of making oral pharmaceutical compositions that contain substantially crush resistant drug containing microparticles. The microparticles may contain an active pharmaceutical agent, a polymer and a plasticizer. The microparticles may be uncoated (so as to impart an immediate release profile) or coated so as to impart an extended release (ER), delayed release (DR) or delayed extended release (DER) profile. One or more of the populations of microparticles may be coated with a taste masking composition. The methods may produce oral compositions such as orally disintegrating tablets that contain one or more these types of microparticles in order to further customize the release profile. Also disclosed are the oral compositions, per se, and methods of using same for their intended purposes.
Abstract:
In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.
Abstract:
A rotary die system that includes first and second axially aligned, coacting rotary dies positioned adjacent one another. Each die includes a working surface having a plurality of recesses defined therein. The recesses in the first die are each configured to align with a recess in the second die to form a product cavity upon coaction of the first and second dies. The product cavity is configured to receive a product. Each recess in at least one of the first or second dies includes a pin therein that is configured to puncture a film that at least partially surrounds the product.
Abstract:
The invention relates to a pharmaceutical formulation comprising 40-O-(2-hydroxy)ethyl-rapamycin in a high drug load part and an immediate release part. In addition, the invention relates to a formulation comprising 40-O-(2-hydroxy)ethyl-rapamycin in a first layer and a surfactant in a layer beneath the first layer. The pharmaceutical composition is particularly suitable for use as a medicament.
Abstract:
Abstract The present invention relates to a coated pharmaceutical composition containing regorafenib, a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof and its process of preparation and its use for treating disorders.